Medicare Enrolled
Dr. Mudussara Khan, MD
Hematology · Daytona Beach, FL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Khan from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Khan?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Khan
Dr. Mudussara Khan is a hematology specialist in Daytona Beach, FL, with 18 years of NPI registration. Based on federal Medicare data, Dr. Khan performed 46,184 Medicare services across 2,098 unique beneficiaries.
Between the years covered by Open Payments, Dr. Khan received a total of $11,435 from 82 pharmaceutical and/or device companies across 667 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Khan is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ 46,184 Medicare services
$11,435 industry payments
Florida License Status
FL DOH · MQA1
Active license
None
Board action on record
0
Recent admin complaints
| Profession | License # | Status | Expires | Board Action |
|---|---|---|---|---|
| Medical Doctor | 114473 | Clear | January 31, 2027 | — |
Data from Florida Department of Health Medical Quality Assurance.
License records are public under Chapter 119, Florida Statutes.
Verify directly on FL DOH →
Medicare Practice Summary
Medicare Utilization ↗46,184
Medicare services
Bottom 35% in FL for hematology
Lower Medicare volume may reflect subspecialty focus, hospital-based work, or a higher share of non-Medicare patients.
2,098
Unique beneficiaries
$15
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~2,566 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 17,138 | $0 | $4 |
| Pembrolizumab injection (Keytruda) | 9,600 | $43 | $137 |
| Anti-nausea injection (aprepitant) | 7,020 | $1 | $5 |
| Denosumab injection (Prolia/Xgeva) | 4,260 | $18 | $51 |
| Dexamethasone injection (steroid) | 1,542 | $0 | $3 |
| Complete blood count (CBC) with differential | 1,090 | $8 | $29 |
| Blood draw (venipuncture) | 893 | $8 | $9 |
| Anti-nausea injection (Aloxi/palonosetron) | 870 | $1 | $28 |
| Drug injection, under skin or into muscle | 418 | $10 | $69 |
| Office visit, established patient (30-39 min) | 414 | $95 | $339 |
| Injection of additional new drug or substance into vein | 339 | $12 | $61 |
| Office visit, established patient (20-29 min) | 303 | $64 | $239 |
| Administration of chemotherapy into vein, 1 hour or less | 300 | $97 | $378 |
| Anti-nausea injection (ondansetron/Zofran) | 276 | $0 | $9 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 242 | $1 | $6 |
| Injection, carboplatin, 50 mg | 173 | $2 | $41 |
| Injection, zoledronic acid, 1 mg | 151 | $6 | $69 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 138 | $47 | $189 |
| Hospital follow-up visit, high complexity | 115 | $94 | $285 |
| Injection, diphenhydramine hcl, up to 50 mg | 85 | $1 | $3 |
| Administration of additional new drug or substance into vein, 1 hour or less | 80 | $49 | $178 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 75 | $22 | $84 |
| Infusion, normal saline solution , 1000 cc | 57 | $2 | $7 |
| Administration of chemotherapy into vein, each additional hour | 56 | $21 | $79 |
| Hospital follow-up visit, moderate complexity | 56 | $63 | $197 |
| Infusion into a vein for hydration, 31-60 minutes | 55 | $24 | $156 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 51 | $25 | $89 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 50 | $3 | $11 |
| Initial hospital admission, high complexity | 48 | $134 | $556 |
| New patient office visit (45-59 min) | 46 | $126 | $453 |
| Infusion into a vein for hydration, each additional hour | 44 | $9 | $42 |
| Automated urinalysis | 36 | $2 | $8 |
| Injection of drug or substance into vein | 36 | $27 | $156 |
| Administration of additional new drug or substance into vein using push technique | 29 | $42 | $170 |
| New patient office visit, complex (60-74 min) | 28 | $166 | $585 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 24 | $18 | $59 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 21 | $1 | $7 |
| Red blood count, automated test | 13 | $4 | $10 |
| Initial hospital admission, moderate complexity | 12 | $103 | $377 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
38.0% high complexity
55.1% medium
6.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$11,435
Total received (2018-2024)
Avg $1,634/year across 7 years
Top 39% in FL for hematology
82
Companies
667
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$10,732 (93.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$703 (6.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,515
2023
$2,584
2022
$1,413
2021
$24
2020
$759
2019
$1,902
2018
$2,238
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,283
Celgene Corporation
$670
Genentech USA, Inc.
$597
AstraZeneca Pharmaceuticals LP
$566
PFIZER INC.
$547
E.R. Squibb & Sons, L.L.C.
$525
Merck Sharp & Dohme LLC
$398
Janssen Biotech, Inc.
$386
Merck Sharp & Dohme Corporation
$377
Amgen Inc.
$369
Gilead Sciences, Inc.
$321
Seattle Genetics, Inc.
$303
GENZYME CORPORATION
$280
ABBVIE INC.
$252
Seagen Inc.
$252
Ipsen Biopharmaceuticals, Inc
$242
Lilly USA, LLC
$237
Incyte Corporation
$212
Bayer HealthCare Pharmaceuticals Inc.
$190
Astellas Pharma US Inc
$182
Eisai Inc.
$155
Daiichi Sankyo Inc.
$155
BeiGene USA, Inc.
$143
Bayer Healthcare Pharmaceuticals Inc.
$118
Regeneron Healthcare Solutions, Inc.
$117
Takeda Pharmaceuticals U.S.A., Inc.
$114
Kite Pharma, Inc.
$110
Boehringer Ingelheim Pharmaceuticals, Inc.
$104
Exelixis Inc.
$100
TAIHO ONCOLOGY, INC.
$92
EMD Serono, Inc.
$90
Pharmacosmos Therapeutics Inc.
$83
TerSera Therapeutics LLC
$80
Stemline Therapeutics Inc.
$77
TESARO, Inc.
$77
SOBI, INC
$71
G1 Therapeutics, Inc.
$71
Puma Biotechnology, Inc.
$69
Blueprint Medicines Corporation
$66
Janssen Pharmaceuticals, Inc
$66
ARRAY BIOPHARMA INC
$66
EISAI INC.
$66
JAZZ PHARMACEUTICALS INC.
$66
Foundation Medicine, Inc.
$64
PharmaEssentia USA Corporation
$57
Lexicon Pharmaceuticals, Inc.
$53
GlaxoSmithKline, LLC.
$51
Mirati Therapeutics, Inc.
$43
CSL Behring
$39
MEDIVATION FIELD SOLUTIONS LLC
$39
MorphoSys, US Inc.
$38
SANOFI-AVENTIS U.S. LLC
$38
Array BioPharma Inc.
$34
AbbVie, Inc.
$34
Smith & Nephew, Inc.
$33
Myriad Genetic Laboratories, Inc.
$33
Genmab U.S., Inc.
$30
CTI BioPharma Corp.
$30
RECORDATI_RARE_DISEASES_INC.
$29
Alexion Pharmaceuticals, Inc.
$28
Heron Therapeutics, Inc.
$28
Alnylam Pharmaceuticals Inc.
$27
Horizon Therapeutics plc
$26
Clovis Oncology, Inc.
$26
Rigel Pharmaceuticals, Inc.
$25
Taiho Oncology, Inc.
$25
Teva Pharmaceuticals USA, Inc.
$25
AMAG Pharmaceuticals, Inc.
$25
NanoString Technologies, Inc.
$24
Adaptive Biotechnologies Corporation
$22
Emmaus Medical, Inc.
$18
Global Blood Therapeutics, Inc.
$18
Sobi, Inc
$17
Coherus Biosciences Inc.
$16
PUMA BIOTECHNOLOGY, INC.
$16
Pharmacyclics LLC, An AbbVie Company
$16
Agios Pharmaceuticals, Inc.
$15
Kyowa Kirin, Inc.
$13
Aurobindo Pharma USA, Inc.
$13
Dova Pharmaceuticals
$13
Secura Bio, Inc.
$9
Veracyte, Inc.
$3
Top 3 companies account for 22.3% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · AYVAKIT · Abraxane · Afstyla · Alecensa · Avastin · BENDEKA · BESREMI · BOSULIF · BRACANALYSIS CDX · BRAFTOVI · BRUKINSA · Bavencio · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · COSELA · CYRAMZA · Cabometyx · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELITEK · ENHERTU · ENJAYMO · ERLEADA · Endari · Enhertu · Epkinly · Erleada · FARYDAK · FERAHEME · FOUNDATIONONE · FRUZAQLA · Fabhalta · GAZYVA · GILOTRIF · GIVLAARI · Halaven · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Idelvion · Imbruvica · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · KRYSTEXXA · Kyprolis · LENVIMA · LIBTAYO · LONSURF · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · MVASI · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OJJAARA · OPDIVO · OPDUALAG · OXBRYTA · Onivyde · Orserdu · PADCEV · PEMAZYRE · PICO · PIQRAY · PLUVICTO · PROMACTA · PROSIGNA ASSAY · Padcev · Perjeta · Polivy · Pomalyst · Poteligeo · REBLOZYL · RYBREVANT · RYDAPT · Revlimid · Rituxan Hycela · Rubraca · SANDOSTATIN LAR · SARCLISA · SCEMBLIX · SOMATULINE DEPOT · SUSTOL · SUTENT · SYLVANT · Somatuline Depot · Stivarga · TAGRISSO · TASIGNA · TECENTRIQ · TIBSOVO · TIVDAK · TUKYSA · Tavalisse · Tecentriq · Trodelvy · ULTOMIRIS · Udenyca · VENCLEXTA · VERZENIO · VONJO · VOTRIENT · Vanflyta · Venclexta · Vitrakvi · Vonjo · Vyloy · XALKORI · XARELTO · XOSPATA · XTANDI · Xermelo · Xofigo · Xospata · Xtandi · Yescarta · ZEJULA · ZEPZELCA · ZYTIGA · Zevalin · Zoladex · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (94%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $25 per 100 Medicare services performed
Geographic Context
Hematologists within 10 mi
9
Per 100K population
1.6
County median income
$66,581
Nearest hospital
ADVENTHEALTH DAYTONA BEACH
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Khan is a mixed practice specialist, with moderate Medicare volume, with low-engagement industry engagement, with 18 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Khan experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Khan performed 17,138 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Khan receive payments from pharmaceutical companies?
Yes. Dr. Khan received a total of $11,435 from 82 companies across 667 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Khan's costs compare to other hematologists in Daytona Beach?
Dr. Khan's average Medicare payment per service is $15. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Khan) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematologists in Daytona Beach
Browse hematologists in Daytona Beach ranked by procedure volume and transparency data.
Highest volume
Top Hematologists in FL
Hematologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematologists in FL
Which FL hematologists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology